Technical considerations in percutaneous hepatic perfusion - A multi-center experience

Journal of Extra-Corporeal Technology

Volumn 43, Issue 1, 2011, Pages 30-33

  Antoine, Radcliffe A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer treatment; Melphalan; Ocular melanoma; PHP; Regional therapy

Indexed keywords

MELPHALAN;

ADULT; ARTICLE; AZYGOS VEIN; BALLOON CATHETER; CANCER THERAPY; CLINICAL ARTICLE; FEMALE; FEMORAL VEIN; HUMAN; INFERIOR CAVA VEIN; LIVER CANCER; LIVER PERFUSION; LIVER TOXICITY; MALE; METASTASIS; MINIMALLY INVASIVE SURGERY; NEUTROPENIA; PRIMARY TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS CIRCULATION;

EID: 79952908290     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ravikumar TS, Pizzorno G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol. 1994;12:2723-36. (Pubitemid 24379662)
2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
3. Rothenberg MC, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin interim results of a phase III trial. J Clin Oncol. 2003;21:2059-69. (Pubitemid 46606353)
4. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19:2687-95. (Pubitemid 32441374)
5. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239-51. (Pubitemid 18066234)
6. Farma JM, Pingpank JF, Libutti SK, et al. Percutaneous hepatic perfusion (PHP) with melphalan for patients with metastatic melanoma (MM) to the liver. Abstract 10068. Surgery Branch, National Cancer Institute.
7. Alexander HR, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5:416-24.
8. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465-74.